As the news keeps coming in fast and furious on the coronavirus pandemic, most of it upsetting, there is some positive news to report.  BCW Member Regeneron today announced that it has already begun trials for a COVID-19 treatment. While it won’t happen overnight, it is comforting to know that a leader right here in Westchester and a member of the BCW is taking steps to combat the virus. 

Regeneron announced that it has launched a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19 infection. This U.S.-based trial will begin at medical centers in New York, and will assess the safety of adding Kevzara to usual supportive care. Kevzara, a fully-human monoclonal antibody, may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19.

The multi-center, double-blind, Phase 2/3 t